![]() The new data from Pfizer and BioNTech comes one day after a study from the U.S. Our goal is to provide broader immunity against COVID-19 caused by SARS-CoV-2, including Omicron and other circulating strains.” “In the next step and as part of our science-based approach we will continue to evaluate the cross-neutralization of the adapted vaccine against new variants and sublineages. Ugur Sahin, CEO and Co-founder of BioNTech said in the statement. “These data demonstrate that our BA.4/BA.5-adapted bivalent vaccine works as conceptually planned in providing stronger protection against the Omicron BA.4 and BA.5 sublineages,” Dr. The bivalent shot was found to lead to a 9.5 fold increase in antibody levels for adults aged 18 to 55, compared to pre-booster levels. The traditional monovalent booster shots led to a 2.9 fold increase in antibody levels in people over age 55 compared to pre-booster levels. ![]() ![]() New data finds bivalent boosters may result in more protection, especially for people over 55Īccording to the data published by Pfizer and BioNTech, in people over age 55 the bivalent booster shot was linked to an over 13-fold increase in antibody levels compared to pre-booster levels. 31 for people 12 years and older, and on Oct. The Food and Drug Administration authorized these bivalent COVID-19 boosters on Aug. The companies announced the findings from phase 2/3 studies, but those findings were not yet peer-reviewed.īivalent COVID-19 boosters that target both the original form of the coronavirus and the currently circulating BA.4 and BA.5 Omicron variants are now available in the United States for people as young as 5 years of age. Pfizer and BioNTech said in a press release that people who received their bivalent booster shots had far higher levels of antibodies to fight SARS-CoV-2, than people who received previous booster shots. With the COVID-19 vaccines, there is already a long track record of safety to support the new boosters.The new COVID-19 boosters were authorized before being tested on humans, but experts say that they are still safe.The FDA has authorized new COVID-19 bivalent boosters for children as young as 5.Pfizer and BioNTech announced in a press release that bivalent booster shots result in far more antibodies to fight SARS-CoV-2, according to study results.Share on Pinterest Fat Camera/Getty Images
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |